Barclays Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $16
Barclays Reaffirms Their Buy Rating on Orchestra BioMed Holdings (OBIO)
Orchestra BioMed Hldgs Analyst Ratings
Barclays Initiates Orchestra BioMed(OBIO.US) With Buy Rating, Announces Target Price $16
Orchestra BioMed Initiated With an Overweight at Barclays
H.C. Wainwright Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $14
Chardan Capital Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $20
Orchestra BioMed Holdings: Strategic Financial Developments and Clinical Progress Justify Buy Rating
Orchestra BioMed Hldgs Analyst Ratings
H.C. Wainwright Initiates Orchestra BioMed(OBIO.US) With Buy Rating, Announces Target Price $14
Piper Sandler Maintains Orchestra BioMed(OBIO.US) With Buy Rating, Maintains Target Price $15
Piper Sandler Remains a Buy on Orchestra BioMed Holdings (OBIO)
Buy Rating Affirmed for Orchestra BioMed on Strong Financials and Promising BackBeat CNT Developments
Orchestra BioMed Sees Expected Operating Cash Runway Into 2H of 2026 Based on Internal Forecast >OBIO
Orchestra BioMed Holdings Price Target Announced at $15.00/Share by B. Riley Securities
Orchestra BioMed Hldgs Analyst Ratings
B. Riley Starts Orchestra BioMed Holdings With Buy Rating, $15 Price Target
Orchestra BioMed Hldgs Analyst Ratings
Orchestra BioMed Hldgs Analyst Ratings
Piper Sandler Sticks to Its Buy Rating for Orchestra BioMed Holdings (OBIO)